Bioaffinity Technologies, Inc. (BIAF) - Form 8-K Summary
Business Context and Reporting Period
Bioaffinity Technologies, Inc., a Delaware corporation, filed this Current Report on Form 8-K on April 1, 2024. The filing serves to disseminate a press release containing financial information for the fiscal year ended December 31, 2023. The company is classified as an emerging growth company and trades on The Nasdaq Stock Market LLC under the symbols BIAF (Common Stock) and BIAFW (Warrants).
Key Financial Metrics
The provided filing text acts as a cover document referencing a press release (Exhibit 99.1) for detailed financial data. Consequently, specific numerical values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this text. The filing text does not provide a clear value for any specific financial metric.
Material Changes
No material changes versus the prior comparable period are detailed within the text of this Form 8-K. The document solely announces the issuance of the press release regarding the 2023 year-end results.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and the attached press release shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into any other SEC filings. No specific guidance, management commentary, risks, or contingencies are described in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for the actual financial figures for the year ended December 31, 2023.
- Verify the company's status as an emerging growth company and its implications for financial reporting.
- Confirm the trading status of Common Stock (BIAF) and Warrants (BIAFW) on Nasdaq.
- Note that the financial data in the press release is not incorporated by reference into future SEC filings.